

Article

Fast-forming hydrogel with ultralow polymeric content as an artificial vitreous body

Accepted Manuscript

Publication reference:

Hayashi, K., Okamoto, F., Hoshi, S. *et al.* Fast-forming hydrogel with ultralow polymeric content as an artificial vitreous body. *Nat Biomed Eng* **1**, 0044 (2017).

DOI of published article:

<https://doi.org/10.1038/s41551-017-0044>

1
2 *Submitted to Nature Biomedical Engineering*
3 *submitted December 9, 2016*
4 *revised January 28, 2017*
5

6 **Article**
7

8 **Fast-forming hydrogel with ultralow polymeric content**
9 **as an artificial vitreous body**
10

11
12 Kaori Hayashi¹, Fumiki Okamoto (co-first author)*², Sujin Hoshi², Takuya Katashima³, Denise
13 Zujur¹, Xiang Li⁴, Mitsuhiro Shibayama⁴, Elliot P. Gilbert⁵, Ung-il Chung¹, Shinsuke Ohba¹,
14 Tetsuro Oshika², Takamasa Sakai*^{1,6}
15

16
17 1. Department of Bioengineering, Graduate School of Engineering, The University of Tokyo,
18 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, Japan

19 2. Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai,
20 Tsukuba, Ibaraki, 305-8575 Japan

21 3. Department of Macromolecular Science, Graduate School of Science Osaka University
22 1-1 Machikaneyama-cho, Toyonaka, Osaka, 560-0043, Japan

23 4. Institute for Solid State Physics, The University of Tokyo, 5-1-5 Kashiwanoha, Kashiwa,
24 Chiba, 277-8583, Japan

25 5. Australian Centre for Neutron Scattering, Australian Nuclear Science and Technology
26 Organisation, Locked Bag 2001, Kirrawee DC, NSW 2232, Australia

27 6. PREST, JST
28

29 * *To whom correspondence should be addressed.*
30

31 **Summary Paragraph**

32 Degradation-induced swelling in implanted hydrogels can cause severe adverse reactions to
33 surrounding tissues. Here, we report a new class of hydrogel with extremely low swelling
34 pressure, and demonstrate its use as an artificial vitreous body. The hydrogel has ultralow
35 polymer content (4.0 g/L), low cytotoxicity, and forms in situ in 10 minutes via the crosslinking
36 of clusters of highly branched polymers of tetra-armed poly(ethylene glycol) pre-polymers.
37 After injection and gelation in the eyes of rabbits, the hydrogel functioned as an artificial
38 vitreous body for over a year without adverse effects, and proved effective for the treatment of
39 retinal detachment. The properties of the cluster hydrogel make it a promising candidate as an
40 infill biomaterial for a range of biomedical applications.

41 **Main text**


42 ***Biomedical Application of Injectable hydrogels***

43 If a material can be introduced without a surgical procedure, treats the disease, and does not
44 harm surrounding tissues throughout its full lifecycle *in vivo*, this represents a significant
45 advance as a biomaterial. Such minimally invasive installation can be achieved using
46 hydrogels by simply injecting a polymer solution into a target space, followed by crosslinking
47 ¹⁻⁴. The solution eventually becomes a hydrogel (**Figure 1, top**) and fills the space inside the
48 body. However, with regard to the final destination, conventional hydrogels have undesirable
49 properties (i.e. swelling) that compromise their morphological and mechanical compatibility *in*
50 *vivo*. Immediately after installation, such *in situ*-forming hydrogels have a higher osmotic
51 pressure (Π_{os}) than the physiological aqueous environment. Due to the difference in osmotic
52 pressure, the hydrogel absorbs water from the surrounding environment, resulting in swelling.
53 The swelling induces an elastic pressure within the hydrogel (Π_{el}) that acts to oppose swelling.
54 Since Π_{os} is much larger than Π_{el} in a good solvent, most hydrogels swell in aqueous conditions
55 with a swelling pressure of Π_{sw} .

56
$$\Pi_{sw} = \Pi_{os} - \Pi_{el} \quad (1)$$

57 These pressures get balanced after a certain magnitude of swelling, achieving an equilibrium

58 swollen state ($\Pi_{sw} = 0$)⁵. It is noteworthy that this equilibrium is transient since hydrogel
59 degradation decreases Π_{el} and shifts the equilibrium to a more swollen condition, leading to
60 extra swelling.^{6,7} Because conventional hydrogels degrade on a long-term basis *in vivo*, extra
61 swelling may be delayed, but cannot be prevented, even in the case of “non-swellable”
62 hydrogels⁸. Extra swelling has caused serious adverse reactions in ophthalmological
63 applications. For example, Mira Gel[®] was commercialized in the 1980s as an eye buckle for
64 the treatment of detached retinas^{9,10}; more than 7 years after installation, the degraded Mira
65 Gel began to swell in the eye socket and eventually compressed the eyeball, resulting in
66 blindness in some cases^{11,12}. Based on the equation (1), the maximum Π_{sw} that can be exerted
67 by the hydrogel is Π_{os} . To completely eliminate the problems caused by swelling, it is
68 important to reduce Π_{os} of hydrogels.



69
70 **Figure 1. (a) Schematic illustration of gelation processes of conventional TetraPEG**
71 **hydrogel and Oligo-TetraPEG hydrogel. In the conventional TetraPEG hydrogel system,**
72 **mutually reactive TetraPEGs are simply mixed and reacted with each other to form the**
73 **hydrogel. In the case of the Oligo-TetraPEG hydrogel system, first mutually reactive**
74 **TetraPEGs were mixed in TetraPEG-SH excess and TetraPEG-MA excess conditions to**
75 **form highly branched polymeric clusters instead of hydrogels (Oligo-TetraPEGs). In the**
76 **second *vivo* process, mutually reactive Oligo-TetraPEGs were mixed to form Oligo-**
77 **TetraPEG hydrogel. (b) (c) and (d) show the storage modulus, G' , (circles) and loss**
78 **modulus, G'' , (triangles) as a function of frequency, ω , below, at and above the gelation**
79 **threshold, respectively. In the region below the gelation threshold (b, $c_0 = 60$ g/L, $r = 0.15$),**
80 **the system is in the sol state and $G' < G''$. At the gelation threshold (c, $c_0 = 60$ g/L, $r = r_c =$**
81 **0.16), the system transforms from a sol to a gel and shows a unique power law behaviour,**
82 **$G' \approx G'' \approx \omega^\beta$. Above the gelation threshold (d, $c_0 = 60$ g/L, $r = 0.17$), the system is in the**
83 **gel state and $G' > G''$ in a wide range of ω . All the experiments were performed in triplicate**
84 **and the data were averaged for each ω . The lengths of error bars (S.D.) are smaller than**
85 **the size of symbols.**

86

87

88 One of the simplest methodologies for reducing Π_{os} is to decrease the polymer
89 concentration^{13,14}; however, the inherent, critical problem of this approach is the challenge of
90 gel formation. Even in an ideal model gel system (Tetra-PEG (TP) gel)^{15,16}, the lowest
91 gelation polymer concentration is 6.0 g/L with 7 hours being required for gelation (**Figure 2a**),
92 the latter far exceeding the time scale of surgery. To prepare an *in situ*-forming hydrogel with
93 a lower polymeric content, and, in addition, that can efficiently form a three-dimensional (3D)
94 polymer network within a reasonable time frame, the design and fabrication of a brand new
95 class of polymeric modules is essential. Here, we describe an *in situ*-forming hydrogel system
96 that can be formed using an extremely low polymer content (~ 4.0 g/L) within 10 minutes. We
97 demonstrate the application of the hydrogel as an artificial vitreous body for treating retinal
98 detachment.


99

100 ***Design of Fast-forming Hydrogels with Low-Polymer Content***

101 At the beginning of conventional crosslinking reaction of polymers (**Figure 1a, top**), the system
102 is still a solution, where the loss modulus (G'') is larger than the storage modulus (G') in the
103 whole frequency region (**Figure 1b**). Here, G'' and G' are indicators of the liquid-like and

104 solid-like nature of the material, respectively. During the gelation, the polymer chains are
105 connected to each other to form a highly branched polymeric structure (polymeric clusters).
106 The polymeric clusters further grow and eventually form a 3D polymer network percolating
107 through space at the gelation point. At the gelation point, the system transforms from a sol to
108 a gel, and shows a unique power law behaviour, i.e., $G' \approx G'' \sim \omega^\beta$ (**Figure 1c** and
109 **Supplementary Figure 1**)^{17,18}. Above the gelation point, the system becomes a gel, which
110 has no fluidity, and G' becomes larger than G'' over a wide range of ω (**Figure 1d**). In our
111 novel system, we separate the challenge of gelation at low polymer content into two processes
112 (**Figure 1a, bottom**). In the first process, the reaction is intentionally stopped immediately
113 prior to the gelation point (**Figure 2a**), at which stage polymeric clusters nearly percolate
114 through the system. The resulting Oligo-TetraPEG exhibits a unimodal size distribution of up
115 to 90 nm (**Supplementary Figure 2**), which is much larger than those of conventional hyper-
116 branch polymers^{19,20}, suggesting that the Oligo-TetraPEG has a highly branched structure. In
117 the second process, the Oligo-TetraPEGs are co-crosslinked as individual modules to
118 expeditiously form a hydrogel (Oligo-TetraPEG (Oligo-TP) hydrogels).

119




120
 121 **Figure 2. (a) Fabrication process for Oligo-TetraPEG hydrogel through the two step**
 122 **process. In the first process, TetraPEG-SH and TetraPEG-MA were mixed in non-**
 123 **stoichiometric conditions to form SH-excess and MA-excess Oligo-TetraPEGs. In the**
 124 **second process, these Oligo-TetraPEG solutions were equally diluted and mixed in equal**
 125 **amount to form Oligo-TetraPEG hydrogels. (b) Sol-gel phase diagram: the relationship**
 126 **between initial polymer concentration (c_0) and mixing ratio of TetraPEG-SH to total**
 127 **polymer concentration ($r = [\text{TetraPEG-SH}]/([\text{TetraPEG-SH}] + [\text{TetraPEG-MA}])$) at sol-**
 128 **gel transition points. The conditions inside the dotted line produced gels, while the**
 129 **conditions outside did not. All the experiments were performed in triplicate and averaged.**
 130 **The lengths of error bars (S.D.) are smaller than the size of symbols.**

131

132 *Fabrication and Characterization of Oligo-TetraPEG hydrogels*

133 To systematically form Oligo-TetraPEGs, we utilized mutually reactive tetra-armed
 134 prepolymers including tetra-armed polyethyleneglycol (PEG) with thiol termini (TetraPEG-
 135 SH) and maleimide termini (TetraPEG-MA) (**Figure 2a**)²¹. First, we investigated the critical
 136 ratio forming hydrogels (r_c) by tuning the molar ratio of these prepolymers ($r = [\text{TetraPEG-SH}]$
 137 $/ ([\text{TetraPEG-SH}] + [\text{TetraPEG-MA}])$) for each initial polymer concentration (c_0). As shown
 138 in **Figure 2b**, the stoichiometric conditions ($r_c = 0.5$) produced hydrogels in the region $c_0 > 6.0$

139 g/L, and the r region that produced hydrogels decreased with a decrease in c_0 . The Oligo-
 140 TetraPEGs are, thus, formed in the sol region close to the sol-gel transition line. In the case of
 141 60 g/L, MA-excess and SH-excess Oligo-TetraPEGs were formed at $r = 0.13$ and 0.87 ,
 142 respectively ($r_c = 0.16$ and 0.83). Based on UV spectroscopy, nearly all minor species reacted
 143 with excess species (**Supplementary Figure 3**), indicating that only the excess functional
 144 group exists on each Oligo-TetraPEGs.



145
 146 **Figure 3.** (a) Gelation time (t_{gel}) of Oligo-TP hydrogels (circles) and TP hydrogels
 147 (triangles) as a function of the polymer concentration (c). (b) Osmotic pressure (Π_{os}) of
 148 Oligo-TP hydrogels as a function of c . (c) SANS measurements from an Oligo-TP solution
 149 and an Oligo-TP hydrogel. (d) Equilibrium storage modulus (G') of Oligo-TP hydrogels
 150 (circles) and TP hydrogels (triangles) as a function of c . All the experiments except for

151 **SANS measurements were performed in triplicate and averaged. The lengths of error bars**
152 **(S.D.) are smaller than the size of symbols. The error bars on the SANS profiles show S.D**
153 **following complete data processing.**

154 In the second process, we co-crosslinked the mutually reactive Oligo-TetraPEGs
155 (MA-excess and SH-excess Oligo-TetraPEGs) to form Oligo-TetraPEG hydrogels (**Figure 2a**).
156 Each Oligo-TetraPEG solution was diluted to the same specific concentration (c) and mixed
157 with each other in equal amount. **Figure 3a** shows the gelation time (t_{gel}) as a function of c .
158 For direct comparison, the results from the conventional one-step method in which hydrogels
159 were directly prepared using the first process with $r = 0.5$, i.e. TetraPEG hydrogels, are also
160 presented. In the case of Oligo-TetraPEG hydrogels, t_{gel} decreased significantly and to nearly
161 within the desired range, i.e. less than 10 minutes. In addition to the shortened t_{gel} , the lowest
162 concentration for gelation and consequently hydrogel formation decreased to $c = 4.0$ g/L; this
163 is lower than that of the hydrogel with the lowest network concentration²². It should be noted
164 that it is difficult to accelerate gelation reactions properly by tuning the reactivity of functional
165 groups; too great a level of active species may result in sudden and heterogeneous gelation,
166 because gelation occurs prior to the homogeneous mixing of prepolymers. In our
167 methodology, we can continuously and easily control the 'distance' to the gel point by tuning r
168 in the first process forming Oligo-TetraPEGs, resulting in the appropriate approach to gelation.
169 Π_{os} of Oligo-TetraPEG hydrogels was a positive finite value and lower than typical eye pressure

170 (~1 kPa) in the region $c < 10$ g/L (**Figure 3b**). Based on small-angle neutron scattering
171 (SANS) measurements, the Oligo-TetraPEG hydrogel has a similar structure to the Oligo-
172 TetraPEG in the high- q region ($0.03 \text{ \AA}^{-1} < q$) together with a highly heterogeneous structure
173 with a wide and smooth size distribution in the low- q region ($q < 0.03 \text{ \AA}^{-1}$) (**Figure 3c**), where
174 q is the magnitude of the scattering vector (a measure of a reciprocal length scale). The typical
175 size of the heterogeneity is smaller than the wavelength of visible light, because the Oligo-
176 TetraPEG hydrogel was transparent. The plateau moduli (G') of Oligo-TetraPEG hydrogels
177 were always higher than those of the conventional hydrogels with the same c (**Figure 3d**),
178 strongly suggest the efficient network formation. The obtained G' values cover the range of
179 those of soft tissues, such as the vocal cord ($10^2 - 10^3$ Pa), vitreous body ($10^0 - 10^1$ Pa) and
180 crystalline lens ($10^2 - 10^3$ Pa) (**Supplementary Movie 1**).

181


182 ***Biocompatibility of Oligo-TetraPEG hydrogels***

183 We next evaluated biocompatibility of Oligo-TetraPEG hydrogel ($c = 7.0$ g/L, $G \approx 4$ Pa) *in vivo*
184 by subcutaneous injection into mice. After 4 weeks, Oligo-TetraPEG hydrogels still remained
185 in the injected site without damage to adjacent tissues (**Figure 4a**). Histological analysis
186 displayed mild infiltration of inflammatory cells in all tested materials. However, expression

187 of CD62L, a marker for inflammatory cells, and encapsulation of the material was detected
188 only in the hydrogel formed from Oligo-TetraPEG crosslinked by small molecules (**Figure 4a**).
189 Due to the similarity between gelation and reverse gelation (disintegration), Oligo-TetraPEGs
190 are not only the raw materials but also the metabolites of Oligo-TetraPEG hydrogels. We thus
191 examined the toxicity of the Oligo-TetraPEGs, and confirmed low toxicities of these specimens
192 *in vitro* (**Figure 4b**) and *in vivo* (**Figure 4c and Supplementary Figure 4**). The low toxicity
193 of Oligo-TetraPEGs may stem from the low permeability of extremely large Oligo-TetraPEGs
194 through the pores of surrounding tissues. These results strongly suggest the biosafety of the
195 full lifecycle of Oligo-TetraPEG hydrogels from formation to disintegration.

196

197



198


199 **Figure 4. (a)** Gel specimens and surrounding tissues, representative images of H&E
 200 staining and immunostaining for CD62L (GFP) in histological sections of mice at 4 weeks
 201 after subcutaneous injection of materials. Asterisks, arrows and rectangles denote
 202 materials, epidermis and the location of views of immunostaining, respectively. Nuclei
 203 were stained with DAPI. Non-specific GFP signal was detected in muscles (red dotted
 204 lines). Scale bars in H&E staining and immunostaining indicate 5 mm and 100 μ m,
 205 respectively. (b) Cell proliferation of NIH3T3 cells cultured with or without Oligo-
 206 TetraPEGs. The data (relative cell number) are expressed as the mean \pm SDs from four
 207 independent experiments. No statistical difference was found between MA-excess Oligo-
 208 TP and control, SH-excess Oligo-TP and control, and MA excess and SH excess Oligo-TPs
 209 in Student t-test analysis. (c) Representative H&E staining images of histological sections
 210 in mice subcutaneously injected with MA-excess and SH-excess Oligo-TPs or PBS.
 211 Sections at 3 days and 2 weeks after the injection are shown. Scale bars, 200 μ m.

212

213 *Applicability to Artificial Vitreous Body*

214 The low cytotoxicity and extremely low swelling pressure of Oligo-TetraPEG hydrogels led us
215 to examine the possibility of its application as an artificial vitreous body. Although a variety
216 of artificial vitreous bodies have been developed, most of them induce an ocular inflammatory
217 reaction in animal studies, preventing clinical application in humans²³⁻²⁷. The
218 biocompatibility and effectiveness of Oligo-TetraPEG hydrogels ($c = 7.0$ g/L, $G \approx 4$ Pa) were
219 evaluated using the normal Dutch pigmented rabbit model (**Supplementary Movie 2**)²⁸. The
220 Oligo-TetraPEG pre-gel solution was compatible with the modality of current small-gauge
221 incision vitreous surgeries and subsequently formed a hydrogel within the vitreous cavity. No
222 significant difference in intraocular pressure was observed between Oligo-TetraPEG hydrogel-
223 injected and balanced salt solution-injected (control) groups throughout the observation period,
224 up to 410 days (**Figure 5a**). Based on slit lamp examinations (**Figure 5b**), images of eyes
225 after dissection (**Figure 5c**), and H&E staining in histological section (**Figure 5g**), neither
226 significant inflammation nor toxic reaction was observed. Remaining Oligo-TetraPEG
227 hydrogel in the vitreous cavity was detected by slit lamp biomicroscopy with a 90-D fundus
228 lens; however it was not detected with histological analysis probably because of technical

229 limitations during histological sectioning. Electroretinography to assess retinal function
230 showed no significant difference in positive waveforms, implicit times and amplitudes between
231 Oligo-TetraPEG hydrogel-injected and control groups. (**Figure 5d, e, f**). Fundus photography
232 revealed that Oligo-TetraPEG hydrogel remained transparent throughout the follow-up period
233 inside the vitreous cavity of the living rabbit eyes (**Figure 6**). Spectral-domain optical
234 coherence tomography revealed neither retinal detachment nor oedema, and the retinal
235 microstructure was not morphologically damaged in either group. By contrast, lens opacity
236 (**Figure 5b**), vitreous opacity (**Figure 5c**) and negative waveforms of electroretinography
237 (**Figure 5d**) due to severe inflammation were observed in the high polymer concentration group
238 ($c = 60$ g/L, $G \approx 9.5$ kPa), similar to the previous artificial vitreous materials. The turbidity in
239 the eyes prevented images of the retina from being obtained through the vitreous. Intraocular
240 pressure could not be measured correctly because of postoperative inflammatory corneal
241 melting in this group as well. In addition, we developed an animal model of retinal
242 detachment and injected Oligo-TetraPEG hydrogel into the vitreous cavity as a vitreous
243 tamponade material to evaluate if pathological conditions could be treated with the gel. As a
244 result, retinal re-detachment was inhibited for 410 days without any complications (**Figure 6**).




245

246 **Figure 5. (a) Changes in the intraocular pressure in the Oligo-TP hydrogel-injected and**
 247 **balanced salt solution-injected (control) groups. No significant difference in intraocular**
 248 **pressure was observed between Oligo-TP hydrogel-injected and control groups**
 249 **throughout the observation period, up to 410 days in Student t-test analysis. The data are**
 250 **expressed as the mean \pm SDs. (b) Anterior segments of rabbit eyes in the Oligo-TP**
 251 **hydrogel-injected, control and TP hydrogel-injected groups on postoperative day 7. (c)**
 252 **Images of eyes after dissection 90 days postoperatively in the Oligo-TP hydrogel-injected,**
 253 **control and TP hydrogel-injected groups. (d) Electroretinography waveform of rabbit**
 254 **eyes in the Oligo-TP hydrogel-injected, control and TP hydrogel-injected groups on**
 255 **postoperative day 90. Bars: 100 μ V and 25 ms. (e) Electroretinography data of a-wave**
 256 **and b-wave implicit time in the Oligo-TP hydrogel-injected and control groups on**
 257 **postoperative day 90. The data are expressed as the mean \pm SDs. (f) Electroretinography**

258 data of a-wave and b-wave amplitudes in the Oligo-TP hydrogel-injected and control
259 groups on postoperative day 90. The data are expressed as the mean \pm SDs. No significant
260 difference in implicit times and amplitudes was observed between Oligo-TP hydrogel-
261 injected and control groups. (g) Representative images of H&E staining in histological
262 section of rabbit eyes at 410 days postoperatively. Scale bars indicate 200 μ m. No apparent
263 inflammation or alteration of retinal microstructure was observed in both Oligo-TP
264 hydrogel-injected and control group.

265



266

267 **Figure 6. Fundus photography of rabbit eyes in the Oligo-TP hydrogel-injected, retinal**
268 **detachment with the Oligo-TP hydrogel-injected and control groups. Arrowhead =**
269 **intentional retinal break.**

270

271 *Discussion*

272 The Oligo-TetraPEG hydrogel was non-invasively installed within a clinically relevant
273 manipulation time and provided low potential swelling pressure throughout the full life cycle
274 *in vivo*. We have further provided a proof of concept for the application of the gel as an
275 artificial vitreous body. Given that their elastic moduli cover the range of those of soft tissues,

276 Oligo-TetraPEG hydrogels will maximize their ability when used as a space-filling implant in
277 unloaded soft tissues, e.g., craniofacial soft tissues; they can be potentially applied to the filling
278 of postsurgical cavities accompanied with re-section of soft tissues that are damaged by trauma,
279 tumor, inflammation, degeneration, and so on, as well as tissue augmentation for cosmetic
280 purposes and the prevention of postoperative adhesions. When complemented by additional
281 functions, such as drug carriers and/or disease modifiers as well as space fillers, these gels could
282 treat a broader range of trauma and degenerative diseases. The repair of sensory and
283 locomotive organs could exploit full life cycle safety because joints, eyes, and ears form
284 confined spaces that house their components and function. Since trauma and degenerative
285 diseases of these organs threaten the quality of life (QOL) of elderly patients, this Oligo-
286 TetraPEG hydrogel may help resolve the gap between life expectancy and healthy life
287 expectancy confronting our progressively ageing society.

288 **Acknowledgements**

289 This work was supported by the Japan Society for the Promotion of Science (JSPS) through
290 Grants-in-Aid for the Graduate Program for Leaders in Life Innovation (GPLLI), the
291 International Core Research Center for Nanobio, Core-to-Core Program A. Advanced Research
292 Networks, and Grants-in-Aid for Young Scientists (A) Grant Number 23700555 to TS,
293 Scientific Research (S) Grant Number 16H06312 to UC, and Scientific Research (C) Grant
294 Number 26462631 to FO. This work was also supported by the Japan Science and
295 Technology Agency (JST) through the S-innovation program and Center of Innovation program
296 (to UC) and PREST (to TS).

297

298 **Methods**

299 **1. Sol-gel transition diagram**

300 TetraPEG-SH and tetraPEG-MA were purchased from NOF Co. (Tokyo, Japan). The
301 molecular weights of Tetra-PEG-SH and Tetra PEG-MA were 10 kg/mol. TetraPEG-SH and
302 tetraPEG-MA were dissolved in citric-phosphate acid buffer (CPB) (pH5.0, salt concentration:
303 5.0 mM); $c_0 = 60$ g/L, $r = 0.13, 0.14, 0.15, 0.16, 0.17, 0.81, 0.82, 0.83, 0.84$ and 0.85 ; $c_0 = 30$
304 g/L, $r = 0.18, 0.19, 0.20, 0.21, 0.22, 0.76, 0.77, 0.78, 0.79$ and 0.80 ; $c_0 = 20$ g/L, $r = 0.23, 0.24,$
305 $0.25, 0.26, 0.27, 0.71, 0.72, 0.73, 0.74$ and 0.75 ; $c_0 = 15$ g/L, $r = 0.27, 0.28, 0.29, 0.30, 0.31,$
306 $0.67, 0.68, 0.69, 0.70$ and 0.71 ; $c_0 = 12$ g/L, $r = 0.31, 0.32, 0.33, 0.34, 0.35, 0.63, 0.64, 0.65,$

307 0.66 and 0.67; $c_0 = 10$ g/L, $r = 0.35, 0.36, 0.37, 0.38, 0.39, 0.59, 0.60, 0.61, 0.62$ and 0.63 . The
308 same amount of the resultant solutions were mixed while tuning the total polymer
309 concentrations (c_0) and the off-stoichiometry ratios of tetra-PEG-SH (r). The resulting
310 solutions were poured into the gap within the double cylinder of a rheometer. The oscillatory
311 shear rheological properties (the storage elastic modulus (G') and the loss elastic modulus (G''))
312 during gelation were measured at 25°C with double cylinder geometry (MCR301; Anton Paar,
313 Switzerland). The applied strain and the frequency were 1.0% and 1.0 Hz, respectively. After
314 12 hours, the frequency-dependence of G' and G'' were measured at a constant strain (1.0%)
315 and frequency of 0.1 - 100 rad/sec. The critical molar ratios were determined as per the criteria
316 of Winter and Chambon^{17,18}.

317

318 **2. Fabrication of Oligo-TetraPEG hydrogel**

319 An appropriate quantity of TetraPEG-SH and TetraPEG-MA were separately dissolved in citric-
320 phosphate acid buffer (CPB) (pH5.0, salt concentration: 5.0 mM). Equal amounts of
321 TetraPEG-SH (7.4 g/L) and TetraPEG-MA (12.6 g/L) solutions were subsequently mixed. In
322 another vial, an equal amount of TetraPEG-SH (12.6 g/L) and TetraPEG-MA (7.4 g/L) solutions
323 were mixed. The two solutions were left to stand at least for 12 h. The two resultant
324 solutions were diluted by using CPB into $c = 4.0, 5.0, 6.0, 7.0, 8.0$ and 9.0 g/L. Equal amounts
325 of equally diluted solutions were mixed; each resulting solution was left to stand at least for 12
326 h.

327

328 **3. Fabrication of conventional Tetra-PEG gel**

329 TetraPEG-SH (4.0, 5.0, 6.0, 7.0, 8.0 and 9.0 g/L) and TetraPEG-MA (4.0, 5.0, 6.0, 7.0, 8.0 and

330 9.0 g/L) were dissolved in citric-phosphate acid buffer (CPB) (pH5.0, salt concentration: 5.0
331 mM). Two TetraPEG-SH and TetraPEG-MA solutions with the same concentration were mixed
332 in equal amounts. The resulting solutions were left to stand at least for 12 h.

333

334 **4. Dynamic Light scattering**

335 DLS measurements were performed on an ALV/CGS-3 goniometer system (ALV, Germany).
336 A He-Ne laser with a power of 22 mW emitting polarized light at 632.8 nm was used.
337 Correlation functions at scattering angle 90° were taken at 25°C. Each resultant solution was
338 diluted to 1.0 g/L. The measurement time was 30 sec with 100 measurements for each sample.

339

340 **5. UV spectra measurement**

341 The reaction conversions of the minor species to excess species were estimated by ultraviolet
342 and visible absorption spectroscopy (V-670; JASCO, Japan). TetraPEG-MA has a specific
343 absorption peak arising from the maleimide group around 300 nm. This peak decreases with
344 the reaction of tetraPEG-MA and tetraPEG-SH. Resultant solutions were poured into the cell
345 (wavelength range: 285-750 nm, optical path length: 5 mm), and the absorbance was measured
346 at a wavelength of 310nm. Here, the concentration of tetraPEG-MA was adjusted so that the
347 absorbance at 310 nm was less than 1.0. Reaction conversion of the minor species to excess
348 species in the solution were calculated by using absorbance at wavelength 310 nm and initial
349 absorbance of tetra-PEG-MA, which was obtained by the calibration curve of tetraPEG-MA at
350 wavelength 310 nm.

351

352 **6. Swelling pressure measurement**

353 Oligo-TetraPEG hydrogels were formed in dialysis membrane with molecular weight cut-off
354 of 1.0k Da. The total weights of specimens and membranes were measured. The hydrogels
355 packed in membranes were immersed into the aqueous solutions of polyvinylpyrrolidone (PVP)
356 with molecular weight of 20k Da. The concentration of PVP solution was tuned from 10 to 120
357 g/L. After 2 days immersion at 25 °C, the weights of specimens were measured. Based on the
358 difference in weight before and after the immersion, the concentrations of PVP that can suppress
359 the swelling of hydrogel specimens (C_{PVP}) were measured. The swelling pressures of hydrogels
360 (Π_{sw}) were calculated by the following equation.^{29,30}

$$361 \quad \Pi_{sw} = 0.878C_{PVP} + 17.25C_{PVP}^2 + 144.1C_{PVP}^3$$

362

363 **7. Small-angle neutron scattering**

364 SANS experiments were performed on the QUOKKA instrument at the OPAL reactor at
365 Australian Nuclear Science and Technology Organization (ANSTO), Sydney, Australia. Three
366 configurations were used to yield a q range from 0.003 to 0.5 Å⁻¹, namely source-to-sample
367 distances of 20m, 8m and 10m, and sample-to-detector distances of 20 m, 8 m and 1.3 m with
368 300 mm detector offset respectively. The wavelength of neutron beam was 5.0 Å with 10%
369 wavelength resolution, with source and sample aperture diameters of 50 mm and 12.5 mm,
370 respectively. All measurements were carried out at 25°C. The Oligo-TetraPEG and Oligo-
371 TetraPEG gel were prepared in D₂O buffer following the procedure of “2. Fabrication of Oligo-
372 TetraPEG hydrogel”.

373

374 **8. Histological evaluation and immunostaining**

375 For the biocompatibility study, some gel specimens*, Oligo-TetraPEGs or citric-phosphate acid

376 buffer (CPB) (pH5.0, salt concentration: 5.0 mM) with NaCl (salt concentration: 149 mM) (200
377 μ l) were subcutaneously injected into the back of 5-week-old Crl:CD1 (ICR) male mice using
378 a 26G needle. Given the Reduction in the 3Rs of animal welfare, we considered the sample size
379 of three was appropriate to confirm the reproducibility of the histological findings in the pilot
380 experiments with no quantitative analysis. Mice were randomly assigned to each group, and we
381 were not blinded to the group allocation and the assessment of results. At 3 days, 2 weeks or 4
382 weeks following the injection, mice were sacrificed and the hydrogels and surrounding tissue
383 were harvested. Collected samples were fixed in 4% paraformaldehyde and embedded in
384 paraffin or OCT compound. Hematoxylin and eosin (H & E) staining was performed on de-
385 paraffinized sections (5-7 μ m). For immunostaining, cryosections (10 μ m) were blocked with
386 PBS containing 0.1% Triton X-100, 3% BSA (Sigma, A7906) and 1% heat inactivated sheep
387 serum (Sigma, S2263) for an hour at room temperature. Sections were then incubated overnight
388 at 4°C with anti-CD62L antibody (Abcam, ab119834; 1:200) and detection was achieved by
389 subsequent incubation with Alexa Fluor® 488 (Abcam, ab172332; 1:500) for an hour at room
390 temperature. Cell nuclei were stained with VECTASHIELD Mounting Medium containing
391 DAPI (Vector Laboratories, H-1200). All experiments were performed in accord with the
392 protocol approved by the Animal Care and Use Committee of The University of Tokyo
393 (#KA14-3).

394 ***Oligo-TetraPEG crosslinked hydrogels:**

395 Dithiol cross-linker (DL-(Dithiothreitol) (DTT)) was purchased from Sigma-Aldrich Japan
396 (Tokyo, Japan). Oligo-TetraPEGs were fabricated with $c_0 = 60$ g/L and $r_c = 0.13$ in CPB
397 (pH5.8, salt concentration: 5.0 mM) with NaCl (salt concentration: 149 mM). DTT was used as
398 a cross-linker for Oligo-TetraPEGs. DTT was dissolved in CPB with NaCl with the equivalent

399 ratios to the number of unreacted functional groups in the Oligo-TetraPEG and mixed with
400 Oligo-TetraPEG solution, resulting in a solution with $c = 13.5$ g/L.

401 ***Oligo-TetraPEG hydrogel:**

402 Oligo-TetraPEGs were fabricated with $c_0 = 60$ g/L and $r_c = 0.13, 0.87$ in CPB (pH5.8, salt
403 concentration: 5.0 mM) with NaCl (salt concentration: 149 mM). These Oligo-TetraPEG
404 solutions were diluted to $c = 7.0$ g/L by using CPB with NaCl and mixed in equal amount.

405 ***Tetra-PEG gel:**

406 TetraPEG-SH and tetraPEG-MA were dissolved in CPB (pH5.8, salt concentration: 5.0 mM)
407 with NaCl (salt concentration: 149 mM) respectively. These two solutions were mixed to
408 produce a resultant solution with $c = 15$ g/L.

409 ***Atelocollagen gel:**

410 Atelocollagen gel (0.4 wt%) was produced from a commercially available bovine dermis
411 atelocollagen (Koken, KOU-IPC-50) following the manufacturer's instructions. Briefly, the gel
412 was obtained by mixing the acidic atelocollagen solution (5 mg/ml) with PBS, NaHCO_3 ,
413 HEPES (pH 7.4) and distilled water in an ice water bath.

414

415 **9. Cell proliferation assay**

416 NIH3T3 cells were obtained from RIKEN Cell Bank and cultured in the following media: basal
417 medium (BM) as a control (DMEM + 10% FBS + 1% pen-strep), BM + MA-excess Oligo-
418 TetraPEG, and BM + SH-excess Oligo-TetraPEG. NIH3T3 cells were periodically
419 authenticated by morphological inspection. We had confirmed no mycoplasma contamination
420 in the cell by a PCR-based mycoplasma detection assay (Venor GeM; Mineva Biolabs, Berlin,
421 Germany). The final concentration of the Oligo-TetraPEG in each medium was 20 mg/L. 5000

422 cells per well (100 μ L) were inoculated in 96-well plates and pre-cultured in BM at 37 °C with
423 5% CO₂ for 24 hours. The medium was then replaced with the experimental ones and changed
424 daily. Cell numbers from 4 independent wells per condition were counted on days 1, 2, 4 and 6
425 using Countess™ Automated Cell Counter (Invitrogen, C10227).

426

427 **10. Animal model for vitreous body**

428 Fourteen normal male Dutch pigmented rabbits, each weighing 2.0 to 3.0 kg, aged 2 to 3 months,
429 were used. The study conformed to the ARVO Statement for the Use of Animals in Ophthalmic
430 and Vision Research, and was reviewed and approved by the Animal Care and Use Committee
431 of University of Tsukuba (#12-109). All procedures were carried out in left eyes with sterile
432 techniques under a surgical microscope (Carl Zeiss Meditec, Inc., Oberkochen, Germany). The
433 animals were anesthetized with intramuscular injection of ketamine hydrochloride (35 mg/kg)
434 and xylazine (5 mg/kg). Topical anesthesia (0.4% oxybuprocaine hydrochloride drops) was
435 applied to the eyes. Pupils were dilated with topical 0.5% phenylephrine hydrochloride, 0.5%
436 tropicamide, and 1% atropine. A standard three-port, 25-gauge trocar-cannula vitrectomy
437 system was used (Alcon Laboratories, Fort Worth, TX). An infusion cannula that delivered a
438 balanced salt solution (BSS; Alcon Japan) was then inserted into the trocar cannula in the 2
439 o'clock position 1mm posterior to the limbus. The remaining two ports required for the insertion
440 of a vitreous cutter and a light pipe in the 11 and 1 o'clock position, respectively, were created
441 using the same method. The vitreous was detached from the retina by aspirating the cortical
442 vitreous visualized with triamcinolone acetonide (Kenacort-A; Bristol-MyersSquibb, Tokyo,
443 Japan). After removal of the vitreous with a vitrectomy cutter, air-fluid exchange was performed
444 in the vitreous cavity. Following air–fluid exchange, 6 eyes of the rabbits were injected Oligo-

445 TetraPEG hydrogel* into the vitreous cavity, and 4 eyes of the rabbits were injected the
446 conventional hydrogel*. A balanced salt solution was injected into the vitreous cavity of the
447 remaining 4 rabbits as controls. Animals were randomized into the groups using envelopes.
448 Sample sizes were based on pilot experiments. All scleral ports were closed with 8-0 Vicryl®
449 after the injection of endotamponade.

450

451 **11. Animal model for retinal detachment**

452 Experimental retinal detachment with a break was made during a 25-gauge vitrectomy in 5
453 normal Dutch pigmented rabbit eyes. After removing the vitreous body, an extrusion needle
454 was used to make a retinal break that was approximately 1/2-1 of the optic disc diameter (DD)
455 in size. The break was made 2 DD inferior to the optic disc. An infusion stream of balanced salt
456 solution was directed under the retinal break, which resulted in a localized retinal detachment
457 of approximately 3-4 DD in size. To achieve retinal reattachment temporarily, air-fluid
458 exchange through the retinal break was performed. After air-fluid exchange, Oligo-TetraPEG
459 hydrogel* was injected into the vitreous cavity of 3 rabbits. A balanced salt solution was
460 injected into the vitreous cavity of the remaining 2 rabbits as controls. Animals were
461 randomized into the groups using envelopes. Sample sizes were based on pilot experiments.
462 All scleral ports were closed with 8-0 Vicryl® after the injection of endotamponade.

463 *** Oligo-TetraPEG hydrogel:**

464 The Oligo-TetraPEG were fabricated with $c_0 = 10$ g/L and $r = 0.32, 0.68$ in CPB (pH5.8, 5.0
465 mM) with NaCl (149 mM). These two Oligo-TetraPEG solutions were diluted to $c = 7.0$ g/L
466 by using CPB with NaCl and mixed in equal amount. The resultant solutions were mixed
467 using the double syringe with three-way cock.

468 ***Conventional hydrogel:**

469 TetraPEG-NH₂ and TetraPEG-NHS (60 g/L) were dissolved in PB (pH7.4, 50 mM) with NaCl
470 (149 mM); the resultant solutions were mixed using the double syringe with three-way cock.

471

472 **12. Intraocular pressure**

473 The intraocular pressure was measured with a tonometer (icare pro; TA01i, Tiolat Oy, Finland)
474 the day before surgery and 3, 7, 28, 90, 150 and 410 days after surgery. Measurements were
475 conducted in a blinded manner.

476

477 **13. Ocular examination**

478 Slit lamp microscopy and indirect ophthalmoscopy were performed with dilated pupils under
479 general anesthesia the day before surgery and 3, 7, 28, 90, 150 and 410 days after surgery.
480 Photographs of the posterior segment of the eye (vitreous and retina) were taken with a fundus
481 camera to evaluate postoperative inflammation of the eyes. Retinal microstructural images were
482 obtained using spectral-domain optical coherence tomography (Cirrus high-definition OCT;
483 Carl Zeiss, Dublin, California, USA). Retinal function was assessed using electroretinography
484 (LW-102; Mayo, Aichi, Japan) 90 days after surgery for 6 eyes of Oligo-TetraPEG hydrogel-
485 injected, 4 eyes of control and 4 eyes of conventional hydrogel-injected groups. Ocular
486 examinations were performed by blinded ophthalmologists.

487

488 **14. Histological evaluation of rabbit eyes**

489 Rabbits were euthanized with an overdose of pentobarbital 410 days postoperatively, and the
490 eyes were enucleated. After enucleation, eyes were fixed in 4% paraformaldehyde and

491 embedded in paraffin or OCT compound. H&E staining was performed on de-paraffinized
492 sections (5-7 μm) and examined under a light microscope.

493

494

495 **Data Availability**

496 The data sets generated during and/or analyzed during the current study are available from the
497 corresponding author on reasonable request.

498

499

500 **References**

- 501 1 Li, Y. L., Rodrigues, J. & Tomas, H. Injectable and biodegradable hydrogels: gelation,
502 biodegradation and biomedical applications. *Chem Soc Rev* **41**, 2193-2221 (2012).
- 503 2 Anseth, K. S., Metters, A. T., Bryant, S. J., Martens, P. J., Elisseeff, J. H. & Bowman,
504 C. N. In situ forming degradable networks and their application in tissue engineering
505 and drug delivery. *J Control Release* **78**, 199-209 (2002).
- 506 3 Ranga, A., Lutolf, M.P., Hilborn H. & Ossipov, D. A, Hyaluronic acid hydrogels formed
507 in situ by transglutaminase-catalyzed reaction. *Biomacromolecules* **17**, 1553-1560
508 (2016).
- 509 4 Pritchard, C. D, O'Shea T. M., Siegwart, D. J., Calo, E., Anderson, D. G., Reynolds, F.
510 M., Thomas, J. A., Slotkin, J. R., Woodard, E. J. & Langer, R. An Infectable thiol-
511 acrylate poly(ethylene glycol) hydrogel for sustained release of methylprednisolone
512 sodium succinate. *Biomaterials* **32**, 587-597 (2011).
- 513 5 Kamata, H., Chung, U., Shibayama, M. & Sakai, T. Anomalous volume phase transition
514 in a polymer gel with alternative hydrophilic-amphiphilic sequence. *Soft Matter* **8**,
515 6876-6879 (2012).
- 516 6 Li, X., Kondo, S., Chung, U. I. & Sakai, T. Degradation Behavior of Polymer Gels
517 Caused by Nonspecific Cleavages of Network Strands. *Chem Mater* **26**, 5352-5357
518 (2014).
- 519 7 Kamata, H., Li, X., Chung, U.-i. & Sakai, T. Design of Hydrogels for Biomedical
520 Applications. *Advanced Healthcare Materials* **4**, 2360-2374 (2015).

- 521 8 Kamata, H., Akagi, Y., Kayasuga-Kariya, Y., Chung, U. & Sakai, T. "Nonswellable"
522 Hydrogel Without Mechanical Hysteresis. *Science* **343**, 873-875 (2014).
- 523 9 Ho, P. C., Chan, I. M., Refojo, M. F. & Tolentino, F. I. The Mai Hydrophilic Implant for
524 Scleral Buckling - a Review. *Ophthalmic Surg Las* **15**, 511-515 (1984).
- 525 10 Tolentino, F. I., Roldan, M., Nassif, J. & Refojo, M. F. Hydrogel Implant for Scleral
526 Buckling - Long-Term Observations. *Retina-J Ret Vit Dis* **5**, 38-41 (1985).
- 527 11 Marin, J. F., Tolentino, F. I., Refojo, M. F. & Schepens, C. L. Long-Term Complications
528 of the Mai Hydrogel Intrasceral Buckling Implant. *Arch Ophthalmol-Chic* **110**, 86-88
529 (1992).
- 530 12 Roldan-Pallares, M., Hernandez-Montero, J., Llanes, F., Fernandez-Rubio, J. E. &
531 Ortega, F. MIRAgel - Hydrolytic degradation and long-term observations. *Arch*
532 *Ophthalmol-Chic* **125**, 511-514 (2007).
- 533 13 Flory, P. J. & Rehner, J. Statistical mechanics of cross-linked polymer networks II
534 Swelling. *J Chem Phys* **11**, 521-526 (1943).
- 535 14 Gennes, P.-G. d. *Scaling concepts in polymer physics* (Cornell University Press,1979).
- 536 15 Sakai, T. *et al.* Design and fabrication of a high-strength hydrogel with ideally
537 homogeneous network structure from tetrahedron-like macromonomers.
538 *Macromolecules* **41**, 5379-5384 (2008).
- 539 16 Sakai, T. Experimental verification of homogeneity in polymer gels. *Polym J* **46**, 517-
540 523 (2014).
- 541 17 Mours, M. & Winter, H. H. Relaxation patterns of nearly critical gels. *Macromolecules*
542 **29**, 7221-7229 (1996).
- 543 18 Winter, H. H. & Mours, M. Rheology of polymers near liquid-solid transitions. *Adv*
544 *Polym Sci* **134**, 165-234 (1997).
- 545 19 Zheng, Y. C., Li, S. P., Weng, Z. L. & Gao, C. Hyperbranched polymers: advances from
546 synthesis to applications. *Chem Soc Rev* **44**, 4091-4130 (2015).
- 547 20 Kainthan, R. K., Muliawan, E. B., Hatzikiriakos, S. G. & Brooks, D. E. Synthesis,
548 characterization, and viscoelastic properties of high molecular weight hyperbranched
549 polyglycerols. *Macromolecules* **39**, 7708-7717 (2006).
- 550 21 Sakai, T., Katashima, T., Matsushita, T. & Chung, U. Sol-gel transition behavior near
551 critical concentration and connectivity, *Polymer Journal* **48**, 629-634 (2016).
- 552 22 Wang, Q. *et al.* High-water-content mouldable hydrogels by mixing clay and a dendritic
553 molecular binder. *Nature* **463**, 339-343 (2010).
- 554 23 Denlinger, J. L. & Balazs, E. A. Replacement of the Liquid Vitreous with Sodium
555 Hyaluronate in Monkeys .1. Short-Term Evaluation. *Exp Eye Res* **31**, 81-99 (1980).

- 556 24 Swindle-Reilly, K. E. *et al.* Rabbit Study of an In Situ Forming Hydrogel Vitreous
557 Substitute. *Invest Ophth Vis Sci* **50**, 4840-4846 (2009).
- 558 25 Pritchard, C. D. *et al.* Evaluation of viscoelastic poly(ethylene glycol) sols as vitreous
559 substitutes in an experimental vitrectomy model in rabbits. *Acta Biomater* **7**, 936-943
560 (2011).
- 561 26 Tao, Y. *et al.* Evaluation of an in situ chemically crosslinked hydrogel as a long-term
562 vitreous substitute material. *Acta Biomater* **9**, 5022-5030 (2013).
- 563 27 Crafoord, S., Andreasson, S. & Ghosh, F. Experimental vitreous tamponade using
564 polyalkylimide hydrogel. *Graef Arch Clin Exp* **249**, 1167-1174 (2011).
- 565 28 Hoshi, S. *et al.* In Vivo and In Vitro Feasibility Studies of Intraocular Use of
566 Polyethylene Glycol-Based Synthetic Sealant to Close Retinal Breaks in Porcine and
567 Rabbit Eyes. *Invest Ophthalmol Vis Sci* **56**, 4705-4711 (2015).
- 568 29 Vink, H. Precision measurements of osmotic pressure in concentrated polymer solutions.
569 *European Polymer Journal* **7**, 1411-1419 (1971).
- 570 30 Horkay, F., Tasaki, I. & Basser, P. J. Osmotic swelling of polyacrylate hydrogels in
571 physiological salt solutions. *Biomacromolecules* **1**, 84-91 (2000).

572

573 **Supplementary Information is linked to the online version of the paper at**

574 **www.nature.com/nature.**

575

576 **Figure Legends**

577

578 **Figure 1.** (a) Schematic illustration of gelation processes of conventional TetraPEG hydrogel
579 and Oligo-TetraPEG hydrogel. In the conventional TetraPEG hydrogel system, mutually
580 reactive TetraPEGs are simply mixed and reacted with each other to form the hydrogel. In the
581 case of the Oligo-TetraPEG hydrogel system, first mutually reactive TetraPEGs were mixed in
582 TetraPEG-SH excess and TetraPEG-MA excess conditions to form highly branched polymeric
583 clusters instead of hydrogels (Oligo-TetraPEGs). In the second *vivo* process, mutually reactive
584 Oligo-TetraPEGs were mixed to form Oligo-TetraPEG hydrogel. (b) (c) and (d) show the
585 dynamic storage modulus, G' , (circles) and loss modulus, G'' , (triangles) as a function of
586 frequency, ω , below, at and above the gelation threshold. In the region below the gelation
587 threshold (b, $c_0 = 60$ g/L, $r = 0.15$), the system is in the sol state and $G' < G''$. At the gelation
588 threshold (c, $c_0 = 60$ g/L, $r = r_c = 0.16$), the system transforms from a sol to a gel and shows a
589 unique power law behaviour, $G' \approx G'' \approx \omega^\beta$. Above the gelation threshold (d, $c_0 = 60$ g/L, $r =$
590 0.17), the system is in the gel state and $G' > G''$ in a wide range of ω . All the experiments were
591 performed in triplicate and the data were averaged for each ω . The lengths of error bars (S.D.)
592 are smaller than the size of symbols.

593

594 **Figure 2.** (a) Fabrication process for Oligo-TetraPEG hydrogel through the two step process.
595 In the first process, TetraPEG-SH and TetraPEG-MA were mixed in non-stoichiometric
596 conditions to form SH-excess and MA-excess Oligo-TetraPEGs. In the second process, these
597 Oligo-TetraPEG solutions were equally diluted and mixed in equal amount to form Oligo-
598 TetraPEG hydrogels. (b) Sol-gel phase diagram: the relationship between initial polymer
599 concentration (c_0) and mixing ratio of TetraPEG-SH to total polymer concentration ($r =$
600 $[\text{TetraPEG-SH}]/([\text{TetraPEG-SH}] + [\text{TetraPEG-MA}])$) at sol-gel transition points. The
601 conditions inside the dotted line produced gels, while the conditions outside did not. All the
602 experiments were performed in triplicate and averaged. The lengths of error bars (S.D.) are
603 smaller than the size of symbols.

604

605 **Figure 3.** (a) Gelation time (t_{gel}) of Oligo-TP hydrogels (circles) and TP hydrogels (triangles)
606 as a function of the polymer concentration (c). (b) Osmotic pressure (Π_{os}) of Oligo-TP
607 hydrogels as a function of c . (c) SANS measurements from an Oligo-TP solution and an Oligo-
608 TP hydrogel. (d) Equilibrium elastic modulus (G') of Oligo-TP hydrogels (circles) and TP
609 hydrogels (triangles) as a function of c . All the experiments except for SANS measurements

610 were performed in triplicate and averaged. The lengths of error bars (S.D.) are smaller than the
611 size of symbols. The error bars on the SANS profiles show S.D following complete data
612 processing.

613

614 **Figure 4.** (a) Gel specimens and surrounding tissues, representative images of H&E staining
615 and immunostaining for CD62L (GFP) in histological sections of mice at 4 weeks after
616 subcutaneous injection of materials. Asterisks, arrows and rectangles denote materials,
617 epidermis and the location of views of immunostaining, respectively. Nuclei were stained with
618 DAPI. Non-specific GFP signal was detected in muscles (red dotted lines). Scale bars in H&E
619 staining and immunostaining indicate 5 mm and 100 μm , respectively. (b) Cell proliferation of
620 NIH3T3 cells cultured with or without Oligo-TetraPEGs. The data (relative cell number) are
621 expressed as the mean \pm SDs from four independent experiments. No statistical difference was
622 found between MA-excess Oligo-TP and control, SH-excess Oligo-TP and control, and MA
623 excess and SH excess Oligo-TPs in Student t-test analysis. (c) Representative H&E staining
624 images of histological sections in mice subcutaneously injected with MA-excess and SH-excess
625 Oligo-TPs or PBS. Sections at 3 days and 2 weeks after the injection are shown. Scale bars,
626 200 μm .

627

628 **Figure 5.** (a) Changes in the intraocular pressure in the Oligo-TP hydrogel-injected and
629 balanced salt solution-injected (control) groups. No significant difference in intraocular
630 pressure was observed between Oligo-TP hydrogel-injected and control groups throughout the
631 observation period, up to 410 days in Student t-test analysis. The data are expressed as the mean
632 \pm SDs. (b) Anterior segments of rabbit eyes in the Oligo-TP hydrogel-injected, control and TP
633 hydrogel-injected groups on postoperative day 7. (c) Images of eyes after dissection 90 days
634 postoperatively in the Oligo-TP hydrogel-injected, control and TP hydrogel-injected groups.
635 (d) Electretinography waveform of rabbit eyes in the Oligo-TP hydrogel-injected, control and
636 TP hydrogel-injected groups on postoperative day 90. Bars: 100 μV and 25 ms. (e)
637 Electretinography data of a-wave and b-wave implicit time in the Oligo-TP hydrogel-injected
638 and control groups on postoperative day 90. The data are expressed as the mean \pm SDs. (f)
639 Electretinography data of a-wave and b-wave amplitudes in the Oligo-TP hydrogel-injected
640 and control groups on postoperative day 90. The data are expressed as the mean \pm SDs. No
641 significant difference in implicit times and amplitudes was observed between Oligo-TP
642 hydrogel-injected and control groups. (g) Representative images of H&E staining in
643 histological section of rabbit eyes at 410 days postoperatively. Scale bars indicate 200 μm . No
644 apparent inflammation or alteration of retinal microstructure was observed in both Oligo-TP

645 hydrogel-injected and control group.

646

647 **Figure 6.** Fundus photography of rabbit eyes in the Oligo-TetraPEG hydrogel-injected, retinal
648 detachment with the Oligo-TetraPEG hydrogel-injected and control groups. Arrowhead =
649 intentional retinal break. Arrowhead = intentional retinal break.

650

651 **Author Contributions**

652 T. S. and U. C. planned and supervised the project. K. H., F. O., S. H., T. K., D. Z., X. L., M.
653 S., E. G. and S.O. designed and performed the experiments. T. O. contributed to discussions
654 throughout the project.

655

656 **Author Information**

657 Reprints and permissions information are available at www.nature.com/reprints.

658

659 The authors declare no competing financial interests.

660

661 Correspondence and requests for materials should be addressed to [sakai@tetrapod.t.u-](mailto:sakai@tetrapod.t.u-tokyo.ac.jp)
662 tokyo.ac.jp.